The global metagenomic sequencing market is estimated at USD 1.96 Billion in 2025 and is projected to reach USD 6.16 Billion by 2032, exhibiting a robust CAGR of 17.8% during the forecast period (2025–2032).
The metagenomic sequencing market growth is driven by the rising adoption of next-generation sequencing (NGS) technologies, growing applications of metagenomics in infectious disease diagnosis, and increasing research in microbiome profiling and antimicrobial resistance. Furthermore, advancements in bioinformatics tools and government-funded genomic research initiatives are enhancing sequencing accuracy and accessibility.
However, high sequencing costs and data interpretation challenges are expected to hinder widespread adoption.
Key Market Insights
The metagenomic sequencing market growth is anticipated to be driven by the rising integration of next-generation sequencing (NGS) technologies with AI-powered bioinformatics platforms, expanding applications in clinical diagnostics, and increasing investments in microbiome research and precision medicine.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/global-metagenomic-sequencing-market
Metagenomic Sequencing Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 1.96 Billion |
|
Estimated Value by 2032 |
USD 6.16 Billion |
|
Growth Rate |
17.8% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The growing adoption of metagenomic next-generation sequencing (mNGS) for infectious disease diagnosis is revolutionizing clinical microbiology. Traditional culture-based methods are often slow and limited to known pathogens, whereas mNGS enables hypothesis-free detection of bacteria, viruses, fungi, and parasites directly from samples such as cerebrospinal fluid, blood, and bronchoalveolar lavage fluid.
In August 2025 review paper “Metagenomic Next-Generation Sequencing (mNGS): Clinical Applications, Translational Challenges, and Future Directions” highlighted the expanding clinical use of mNGS due to its superior diagnostic yield and broad pathogen coverage.
The commercialization of such technologies is further shaping the market landscape. In April 2025, Delve Bio, a key player, introduced Delve Detect, an advanced diagnostic platform capable of identifying over 68,000 pathogens in a single test, showcasing over 20% higher detection efficiency in meningitis and encephalitis cases compared to conventional diagnostics. Additionally, advancements in AI-based bioinformatics tools and cloud-integrated data analysis are improving result accuracy and turnaround times.
Market Trends
The integration of metagenomic sequencing into point-of-care testing is accelerating, enabling faster and more precise detection of respiratory pathogens.
In February 2025, Planet Innovation (PI) was selected as a key technology partner in a USD 25.1 million consortium led by Ginkgo Bioworks, Inc., alongside Jumpcode Genomics, BugSeq, and TGen – Part of City of Hope, in collaboration with the European Health and Digital Executive Agency (HaDEA). The consortium aims to develop Rapid Next-Generation Sequencing for Effective Medical Response (RANGER), a point-of-care metagenomic sequencing solution for the rapid diagnosis of respiratory pathogens in hospitals and healthcare facilities.
The clinical use of metagenomic sequencing is expanding beyond research into routine diagnostic settings, particularly for gastrointestinal infections.
In March 2024, Microba Life Sciences Limited, in partnership with Sonic Healthcare Limited, officially launched MetaPanel, an advanced gastrointestinal pathogen metagenomic test, across Australia. Distributed through Sonic’s subsidiary Douglass Hanly Moir Pathology, the MetaPanel test enables the comprehensive detection of multiple pathogens in a single assay.
Market Opportunities
The introduction of gene-centric computational pipelines is transforming pathogen detection and antimicrobial resistance (AMR) monitoring.
In October 2023, Microbiome published a study by Van Camp et al. on MGS2AMR, an advanced data-mining framework that profiles pathogens and associated AMR genes directly from metagenomic datasets. This marks a significant market opportunity for clinical metagenomic solution providers to develop automated AMR surveillance platforms and diagnostic workflows integrating such tools.
Advances in long-read sequencing are enabling more complete and accurate recovery of microbial genomes from complex samples.
In a May 2023 comparative study (Microbiome 11:105), Orellana et al. demonstrated that long-read sequencing significantly improves genome assembly and temporal tracking in time-series metagenomes. This opens new opportunities for technology developers and service providers to integrate long-read platforms (e.g., Oxford Nanopore, PacBio) into metagenomic workflows.
Analyst View
Key Developments
Competitive Landscape
Global Metagenomic Sequencing Market Segmentation
Regional Insights
Related Reports :